article thumbnail

Alzheimer’s drug Leqembi expected to generate $12.9bn in sales by 2028

Pharmafile

After receiving FDA approval in January 2023, Biogen/Eisai’s new Alzheimer’s disease Leqembi is expected to become a blockbuster, with a predicted $12.9bn predicted to be made in sales between 2023 and 2028. read more

FDA 83
article thumbnail

As Viatris seeks growth in eye care, its Ocuphire-partnered dilation drop Ryzumvi wins FDA nod

Fierce Pharma

Viatris just notched a win on its quest to reach $1 billion in eye care sales by 2028. | The FDA on Wednesday approved Viatris and Ocuphire’s Ryzumvi, also known as phentolamine ophthalmic solution, to treat pharmacologically-induced mydriasis, or dilation of the pupils. The partners plan to make Ryzumvi available in the U.S.

FDA 113
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

STAT+: Lawmaker accuses Amgen of placing profits above patients with dosing for a cancer drug

STAT

Last December, the agency determined the confirmatory trial was not acceptable and asked the company to run yet another trial, which must be completed by February 2028.

Dosage 138
article thumbnail

MSD’s Keytruda wins expanded FDA combo approval in cervical cancer

Pharmaceutical Technology

MSD’s blockbuster immunotherapy, set to lose patent protection in 2028, secures third FDA approval in cervical cancer.

FDA 59
article thumbnail

STAT+: Pharmalittle: We’re reading about FDA eyeing PDUFA changes, compounded weight loss drugs, and more

STAT

Noom will offer its version of compounded semaglutide — the active ingredient in Wegovy and diabetes drug Ozempic — as part of a program personalized for patients, which it says will comply with changing FDA regulations. Noom offers its compounded semaglutide at a starting price of $149 for the first month.

article thumbnail

STAT+: Make America Healthy Again is ringing through statehouses across the U.S.

STAT

  Some of the new measures — like West Virginia’s landmark bill, signed into law Monday , banning most artificial dyes and two preservatives from sale in the state starting in 2028 — highlight how concern over the safety of the U.S. food supply is an increasingly nonpartisan issue.

article thumbnail

Merck’s Welireg becomes first drug for rare VHL tumours in US

pharmaphorum

Merck & Co has extended its range of cancer medicines in the US after claiming FDA approval for Welireg – a drug it acquired as part of its $2.2 This first FDA approval triggers a $50 million payment to former Peloton shareholders, with another $50 million due on commercial launch. Merck paid $1.05 billion in milestone payments.